bimagrumab   Click here for help

GtoPdb Ligand ID: 8086

Synonyms: BYM-338 | BYM338
Compound class: Antibody
Comment: Bimagrumab is an investigational monoclonal antibody designed to treat the pathological muscle loss and weakness caused by the inflammatory muscle depleting disease, sporadic inclusion body myositis (sIBM).
Click here for help
No information available.
Summary of Clinical Use Click here for help
Bimagrumab is being assessed in Phase 2/III clinical trial as a treatment for sporadic inclusion body myositis [1] (NCT01925209) and in Phase 2 trials for sarcopenia (NCT02333331) or as an agent to reduce muscle wasting following hip fracture surgery (NCT02152761).
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Bimagrumab primarily targets the type II activin receptor ACVR2B [2], which is a type II receptor serine/threonine kinase. The antibody also has high affinity for ACVR2A, but this is much lower in comparison to ACVR2B binding.
This action blocks myostatin-induced SMAD pathway signalling, which is hypothesised to improve the formation of skeletal muscle [3-4].